Published: May 22, 2020

Introduction {#sec1}
============

Cisplatin, cis-diamminedichloroplatinum(II) (CDDP), plays a pivotal role in cancer therapy and has been a standard component in the treatment regimens of a wide spectrum of solid tumors including bladder, cervix, head and neck, esophageal, small cell lung cancer, breast cancers, testicular cancer, and neuroblastoma ([@bib5], [@bib9], [@bib38], [@bib60], [@bib61]). It has also been used as salvage therapy in the case that the first-line treatment has failed or in specific situations that preclude the standard treatment ([@bib7], [@bib25]). Despite its therapeutic success, CDDP unfortunately exhibits undesirable dose-dependent side effects such as neurotoxicity, ototoxicity, nausea/vomiting, hepatotoxicity, and particularly nephrotoxicity ([@bib53]). Patients may suffer a progressive and persistent decline in renal function after a successive treatment cycle, which is characterized by a deterioration in the glomerular filtration rate (GFR), massive renal electrolytes loss, and elevated serum urea and creatinine levels ([@bib49]). CDDP-induced nephrotoxicity accounts for up to 60% of all cases of hospital-acquired acute kidney injury (AKI), a disease that is associated with considerable morbidity and mortality ([@bib46]) and has no effective treatment currently.

Although the precise mechanisms involved in CDDP-induced renal failure have not been thoroughly understood, it is generally believed to be multifaceted including injury to nuclear and mitochondrial DNA, production of reactive oxygen species (ROS)/reactive nitrogen species (RNS), activation of apoptosis, initiation of inflammatory response, and altered transport of CDDP into renal epithelial cells ([@bib68]). Moreover, it was found that platinum is preferentially accumulated in the S3 segment of tubular epithelial cells in kidney being 5-fold concentrated than that in blood ([@bib10]), and a lack of means to eliminate excessive Pt(II) in kidney sharply compromises its therapeutic advantage. Despite various methods used to reduce the side effects caused by CDDP, e.g. pre-hydration with mannitol or furosemide, and co-administration with cimetidine or amifostine ([@bib63]), their protective profile are suboptimal and a gap in reducing CDDP-induced nephrotoxicity still remains in the clinic.

Bismuth(III) \[Bi(III)\] compounds, e.g. bismuth (sub)nitrate, were found to be effective inducers of metallothionein (MT) and have been demonstrated to offer protection against the nephrotoxicity caused by CDDP and doxorubicin (Adriamycin) ([@bib20], [@bib32], [@bib34], [@bib43], [@bib58], [@bib66]). Bismuth is a "green" metal and has been used in clinic for the treatment of various diseases for decades, particularly for *Helicobacter pylori* infection ([@bib41]). Bismuth also achieves the highest visceral concentrations in proximal tubule epithelial cells of kidney as platinum does ([@bib18]) but exhibits negligible toxicity in humans, attributable to its glutathione, and multidrug-resistant protein-mediated disposal in mammalian cells ([@bib28]). Thus, there is a great potential for bismuth to be incorporated in cancer chemotherapy to circumvent CDDP-induced nephrotoxicity. It is generally believed that Bi(III) may induce certain cytoprotective biomolecules, i.e., reduced glutathione (GSH) and, in particular MT, which are utilized for the defense of oxidative/nitrosative stress or direct chelation of platinum by MT to ameliorate CDDP-induced nephrotoxicity. However, the precise protective mechanism remains elusive. Moreover, the existing bismuth compounds exhibit relatively low protective efficacy, and new potent neuroprotective agents await to be developed.

Here, we report bismuth tetraphenylporphyrinate \[Bi(TPP)\] as a potent nephroprotective agent both *in vitro* and *in vivo*. Different from previously reported bismuth compounds, Bi(TPP) exhibits protective roles *via* maintaining ROS and ATP levels and eliminating renal platinum and targeting caspase-dependent apoptosis rather than induction of MT. Notably, Bi(TPP) does not interfere with the antitumor activity of CDDP. Therefore, Bi(TPP) has the potential to be incorporated in cancer therapy as an antidote against CDDP-induced nephrotoxicity.

Results {#sec2}
=======

Identification of Cytoprotective Bi(III) Compounds *In Vitro* {#sec2.1}
-------------------------------------------------------------

We first prepared Bi(III) compounds by coordinating Bi(III) (as Bi(NO)~3~) with a series of organic ligands including porphyrin, crown ether, salicylic acid analogs, thiols, etc. ([Figure S1](#mmc1){ref-type="supplementary-material"}). The identity and purity of Bi(III) compounds were confirmed by fast atom bombardment (FAB)/electrospray ionisation (ESI) mass spectrometry and nuclear magnetic resonance spectroscopy (NMR) (see in [Supplemental Information](#appsec2){ref-type="fn"}). The cytotoxicity of synthesized compounds to two mammalian cells was relatively low, with a half cytotoxic concentration (TC~50~) over 100 μM ([Figure S2](#mmc1){ref-type="supplementary-material"}). To identify cytoprotective Bi(III) compounds, a primary phenotypic screening was conducted on a normal human renal proximal tubule cells (HK-2). HK-2 cells were pre-incubated with or without Bi(III) compounds at fixed concentration (100 μM) and then exposed to cytotoxic concentrations of CDDP (10 μM) over a period of 48 h. Any compound that showed protective index (PI) \> 1, where PI was defined as the ratio of survival rate of cells treated with Bi(III) and CDDP to that of CDDP treated alone and had less than 10% cytotoxicity to cells in the absence of CDDP, was considered to be protective. Amifostine, a nephroprotective adjuvant used in cancer chemotherapy, and two reported active compounds, Bi(NO)~3~ ([@bib6]) and BiZn ([@bib8]), as well as three bismuth drugs, i.e., bismuth subsalicylate (BSS, Pepto-Bismol), colloidal bismuth subcitrate (CBS, De-Nol), and bismuth subgallate (BSG, Devrom) were used for comparison. This primary screening generated two categories of active compounds, i.e., Bi(III) tetraphenylporphyrate (Cpd 1) and Bi(III) thiolates (Cpd 6 and Cpd 8) with PI of 3.54, 2.82, and 2.90 for HK-2 cells, respectively. These compounds had much higher PI than amifostine and other Bi(III) compounds with PI no greater than 2 ([Figure 1](#fig1){ref-type="fig"}A). We further demonstrated that Cpd 1 \[Bi(TPP)\] and Cpd 8 \[Bi(NAC)~3~\] ([Figure 1](#fig1){ref-type="fig"}B) protected cells in a dose-dependent manner with the protective potency (EC~50~) of 15.3 and 73.7 μM for HK-2 cells, respectively, under identical conditions ([Figures 1](#fig1){ref-type="fig"}C and 1D).Figure 1*In Vitro* Screening Identifies Bismuth Compounds with Nephroprotective Effects on Kidney Cells(A) Bar chart illustrating the representative protective index of Bi(III) compounds for HK-2 cells.(B) The proposed structures of selected bismuth compounds, Bi(TPP) and Bi(NAC)~3~.(C and D) The dose-dependent protective effects of (C) Bi(TPP) and (D) Bi(NAC)~3~ for HK-2 cells. Data are represented as mean ± SEM. ∗p \< 0.05 ∗∗p \< 0.01, and ∗∗∗p \< 0.001, Student\'s t test, with the significance in comparison to the group of Bi(III) concentration at 0 μM.

*In Vivo* Protective Potency of Bi(III) Compounds in Mouse Model of CDDP-Induced Kidney Injury {#sec2.2}
----------------------------------------------------------------------------------------------

We further evaluated the protective effect of selected Bi(III) compounds on CDDP-induced renal toxicity in a validated mouse model of acute kidney injury. Briefly, groups of mice receiving intraperitoneal injection of a lethal dose (20 mg kg^−1^) of CDDP were administered orally with Bi(III) compounds three times prior to and twice after CDDP treatment as shown in [Figure 2](#fig2){ref-type="fig"}A. The administration of CDDP led to acute renal damage with 10-fold increase in the level of renal toxicity biomarker, blood urea nitrogen (BUN), from 17.7 to 171.1 mg dL^−1^ in comparison to non-treated group ([Figure 2](#fig2){ref-type="fig"}B). The BUN levels were reduced greatly by co-administration with all the three tested compounds, among which Bi(TPP) showed the highest nephroprotective potency with the upregulated BUN level being recovered by \~2.83 folds. No or negligible increase in BUN level was noted when they were used alone, indicative of the non-nephrotoxicity of the tested compound ([Figure 2](#fig2){ref-type="fig"}B). The renal platinum levels were determined 3 days after CDDP injection, and approximately 47.2% decrease in the platinum level was noted in the mouse kidney of Bi(TPP) co-treatment group compared with those of CDDP-alone group ([Figure 2](#fig2){ref-type="fig"}C), indicating that Bi(TPP) could facilitate platinum clearance from renal cells. In a separate experiment, acute renal damage induced by CDDP resulted in around 30% body weight loss 4 days after CDDP treatment ([Figure 2](#fig2){ref-type="fig"}D) and further led to death of all mice within five days ([Figure 2](#fig2){ref-type="fig"}E). In contrast, pre-treatment of Bi(TPP) effectively prevented the death of mice with a survival rate of 66.7%, whereas Bi(NAC)~3~ and BiZn could only rescue 12.5% and 25% of mice, respectively, at the end of the experimental period ([Figure 2](#fig2){ref-type="fig"}E). The body weights of survived mice were recovered to normal ranges within four weeks ([Figure 2](#fig2){ref-type="fig"}D).Figure 2Bismuth Compounds Exerts *In Vivo* Protective Potency against CDDP-induced Renal Damage(A) Schematic representation of the experimental design. Groups of mice were orally administered with Bi(TPP), Bi(NAC)~3~, and BiZn, respectively and then intraperitoneally administered with CDDP. Mice treated with vehicle, Bi(TPP), Bi(NAC)~3~, or BiZn in the absence of CDDP served as control.(B) Bar chart showing the BUN level of groups of mice treated versus untreated with Bi(TPP), Bi(NAC)~3~, and BiZn upon the treatment of CDDP. Data are represented as mean ± SEM. ∗p \< 0.05 ∗∗p \< 0.01, and ∗∗∗p \< 0.001, Student\'s t test.(C) Renal platinum levels were measured in the kidneys of mice from CDDP-alone and CDDP-Bi(TPP) co-administration group three days after CDDP injection. Data are represented as mean ± SEM; n = 4 for CDDP group and n = 6 for CDDP-Bi(TPP) co-administration group; ∗∗p \< 0.01, Student\'s t test.(D) Curves of averaged body weight changes of each group after CDDP injection. Error bars represent means ± SEM from biological replicates.(E) Survival curves showing the protective effects of Bi(TPP) and Bi(NAC)~3~. Eight mice per treatment group were used for the survival studies. p \< 0.001, Mantel-Cox test.(F and G) Pharmacokinetics profiles of (F) plasma bismuth concentration and (G) renal bismuth content. Bi(TPP) was used at 50 mg kg^−1^ following oral administration. Three mice were used for each time point, and data are represented as mean ± SEM.

Oral administration of Bi(TPP) as a representative compound was studied in mice to preliminarily evaluate the pharmacokinetics profile of related Bi(III) compounds. The compound was administered to mice orally. The plasma and kidney of the mice were sampled between 0 and 48 h at different time intervals shown in [Figure 2](#fig2){ref-type="fig"}F. Bi(TPP) displayed a rapid absorption profile with maximum concentration of 16.8 μg L^−1^ (C~max~) reached at 1 h (T~max~). AUC~0--48\ h~ of Bi(TPP) could achieve 370.2 h∙μg L^−1^ with an estimated plasma t~1/2~ of 6 h ([Table S1](#mmc1){ref-type="supplementary-material"}). The renal bismuth content was also profiled over the period of 48 h as shown in [Figure 2](#fig2){ref-type="fig"}G, demonstating the sufficient accumulation of bismuth in kidney.. Taken together, we showed that the tested Bi(III) compounds, in particular Bi(TPP), served as a protective agent against CDDP-induced renal toxicity in mice.

Structure and Activity Relationship of Bi(III) Porphyrins {#sec2.3}
---------------------------------------------------------

To explore the role of Bi(III) and porphyrin ligand, we first compared the protective effect of Bi(TPP) with other metallo-tetraphenylporphyrinates in HK-2 cells. As shown in [Figure 3](#fig3){ref-type="fig"}A, porphyrinates of Fe(III), Cu(II), Co(II), and Zn(II) were also identified to be active with protective index of around 3, whereas negligible or no protection was provided by porphyrinates of either Mn(III) or Ga(III) or the ligand itself. Nevertheless, the protective index of Bi(TPP) was determined to be the best with the highest PI value. We then examined structure-activity relationship (SAR) of Bi(III) porphyrinates and synthesized a series of Bi(III) compounds by complexation with tetraphenylporphyrin and its derivatives ([Figure 3](#fig3){ref-type="fig"}B) as described in the Material and Method section. The *in vitro* screening gave rise to seven Bi(III) porphyrinates with PI values of 1.84--4.58 and three compounds with PI lower than 1 ([Figure 3](#fig3){ref-type="fig"}C). The protective activity and the ClogP of the ligands could be approximately fitted into a third-order equation as shown in inset of [Figure 3](#fig3){ref-type="fig"}C, suggesting that the protective activity of Bi(III) porphyrinates could be finely tuned by altering the lipophilicity of the ligand. Generally, a lipophilic porphyrin ligand with Clog P ranged from 8 to 14 may favor the activity of the compound, as the increased lipophilicity facilitated the passive permeation of small molecules ([@bib2]). The protective effectiveness of two of the most potent Bi(III) complexes with TPP derivatives, Bi(TMOPP) and Bi(TMPP), were further verified in the mouse model under identical condition, as shown in [Figures 3](#fig3){ref-type="fig"}D and 3E. Collectively, we showed that the protective effectiveness of Bi(III) porphyrinate could be optimized by tuning ligand lipophilicity.Figure 3Protective Potency of Bismuth Porphyrin Complexes Could Be Optimized by Varying Lipophilic TPP Ligands(A) Comparison of protective effects of Bi(III)- and other metallo-porphyrins. Bi(TPP) derivatives were synthesized with ligands shown in (B) and their protective activity is shown in (C), with the correlation between protective index of the Bi(III) compounds and ClogP of related porphyrin ligands shown as the inset. (D and E) *In vivo* protective performance of Bi(TMOPP) and Bi(TMPP) is shown as averaged body weight change (D) Error bars represent means ± SEM from biological replicates. and survival rate (E). Eight mice per treatment group were used for the survival studies. p \< 0.001, Mantel-Cox test.

Buffering of CDDP-Regulated Gene Alteration in Key Biological Pathways by Bi(TPP) {#sec2.4}
---------------------------------------------------------------------------------

To gain a global perspective of the protective mechanism(s) of Bi(TPP) toward CDDP-induced nephrotoxicity, we performed transcriptomic analysis on the kidneys of mice treated with either Bi(TPP) (and BiZn for comparison), CDDP, or their combinations. In comparison to vehicle-treated group, CDDP severely altered the transcriptome level of mouse kidney with 2,453 genes being upregulated and 2,250 genes being downregulated (p \< 0.05). However, the co-administration of Bi(TPP) significantly suppressed the upregulated genes by 29.2% (717) and the downregulated genes by 28.7% (646) as shown in the heat maps in [Figure 4](#fig4){ref-type="fig"}A, SET I, and [Figure 4](#fig4){ref-type="fig"}B, SET II, respectively. In contrast, BiZn could only buffer 11.2% (275) and 9.1% (204) genes that were up- and downregulated by CDDP, respectively ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B), in line with its inferior *in vivo* effectiveness to Bi(TPP) as demonstrated earlier. We then examined the expression levels of GSH- and MT-related genes, which were previously considered to be responsible for the protective role of Bi(III) for CDDP-induced nephrotoxicity. We found that GSH-related genes including *Mgst1* and *Mgst2* and MT-related genes including *Mt1* and *Mt2* were significantly upregulated in BiZn-treated group ([Figure 4](#fig4){ref-type="fig"}C). The expressions of some genes were further induced when BiZn and CDDP were used together, including *Gsta3* (1.19 folds), *Gsta4* (1.76 folds), *Gstm6* (3.22 folds), *Mgst1* (2.76 folds), *Mgst2* (8.90 folds), *Mt1* (19.73 folds), and particularly *Mt2* (42.06 fold) ([Figures 4](#fig4){ref-type="fig"}C and [Table S2](#mmc1){ref-type="supplementary-material"}). These results are in agreement with previous reports that the significant upregulation of GSH and MT in kidney contributed greatly to the nephroprotection provided by BiZn and related Bi(III) compounds, e.g. BN, BSN, and CBS ([@bib6], [@bib35], [@bib40], [@bib47]). In contrast to BiZn, Bi(TPP) suppressed the expression of *Mgst2* by 2.34-fold and slightly induced the expression of *Gstt1*, *Gstt2*, *Gstm6*, *Gstm7*, and *Gsta2* by no more than 1.6-fold ([Figure 4](#fig4){ref-type="fig"}C and [Table S2](#mmc1){ref-type="supplementary-material"}). We then compared the expression levels of these genes in the CDDP-alone group with those of the CDDP-Bi(TPP) combination group and found that the genes related to GSH and MT were not significantly upregulated. Instead, the expression of *Mt1* and *Mt2* were largely suppressed to almost normal levels ([Table S2](#mmc1){ref-type="supplementary-material"}). These results suggest the protection provided by Bi(TPP) may represent a new mechanism.Figure 4Whole Transcriptome Analysis Reveals the Nephroprotective Mode of Action of Bi(TPP)(A and B) Venn image and heatmap of whole transcriptome sequencing on kidney extracts from mice receiving treatments of vehicle, Bi(TPP), CDDP, or CDDP + Bi(TPP), n = 3 animals per group. The overlapping sets amid Venn image revealing that the expression of genes (A) in SET I was suppressed over CDDP-induced upregulation and (B) in SET II was induced over CDDP-induced downregulation upon the treatment of Bi(TPP). Heat maps illustrate the scaled average gene expression. A false discovery cut-off rate = 0.05 was used for determining differential gene expression. Blue color indicates low expression, whereas red color indicates high expression.(C and D) Cytoscape analysis showing overrepresented biological process from GO analysis for genes in (C) SET I and (D) SET II. Colors represent the GO group. GO analysis and visualization was performed using the ClueGo Cytoscape plug-in. GO terms are presented as nodes and are clustered together based on the similarity of genes present in each term or pathway. Nodes with multiple colors are associated with more than one process.(E and F) Bubble charts showing KEGG pathway that are significant for genes in (E) SET I and (F) SET II (p \< 0.05). KEGG pathway enrichments are displayed in a scatter diagram, where each point represents the enrichment level, color corresponds to the q-value, and the size corresponds to the number of genes enriched for the given pathway. Red indicates the q-value; the smaller the value, the more significant the pathway enrichment.

Gene ontology (GO) network was created to probe the functional specificity of clusters differentiated between CDDP-alone and CDDP-Bi(TPP) combination groups with respect to biological processes. Genes in SET I were functionally arranged into 15 parental clusters, and the most significantly enriched two clusters were genes related to endopeptidase activity (GO:0004175) and regulation of protein phosphorylation (GO:0001932) with 26 and 24 child terms, respectively ([Figures 4](#fig4){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}C and [Table S3](#mmc3){ref-type="supplementary-material"}). Although the genes in SET II were grouped into 15 clusters among which inorganic cation transmembrane transporter activity (GO:0022890) with 12 child terms was the most significantly enriched cluster ([Figures 4](#fig4){ref-type="fig"}F and [S3](#mmc1){ref-type="supplementary-material"}D and [Table S4](#mmc1){ref-type="supplementary-material"}). The child-annotated terms in endopeptidase activity could be predominantly traced to cysteine-type endopeptidase activity involved in apoptotic process (GO:0097153), which were in close relation to another parent cluster, negative regulation of apoptotic signaling pathway (GO:2001234) as showed in [Figure S3](#mmc1){ref-type="supplementary-material"}C. This provided clues that Bi(TPP) may generically regulate the activity of cysteine-type endopeptidase related to apoptosis process. The genes upregulated by Bi(TPP) were largely related to the annotated term of cation transmembrane transporter activity, wherein gene expression levels of multidrug and toxin extrusion 1 transporter *MATE1/SLC47A1* and copper efflux transporters *ATP7A* and *ATP7B* were increased by 1.23-, 1.41-, and 1.33-folds, respectively ([Table S2](#mmc1){ref-type="supplementary-material"}). The former has been demonstrated to efflux CDDP into the tubular lumen, thus reducing cellular accumulation of CDDP ([@bib48]) and the latter to sequester CDDP into subcellular compartments, limiting CDDP cytotoxicity ([@bib39], [@bib57]). Additionally, the significantly enriched GO terms in SET II genes include acyl-CoA metabolic process (GO:0006637), purine ribonucleotide metabolic process (GO:0009150), fatty acid biosynthetic process (GO:0009062), kidney epithelium development (GO:0072073), and nephron epithelium development (GO:0072006) ([Figure S3](#mmc1){ref-type="supplementary-material"}D), indicating that the action of Bi(TPP) may be associated with cell proliferation and cell respiration.

A Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis showed that genes in SET I are primarily enriched in p53 signaling pathway (20 gene counts, p = 1.70 × 10^−11^), TNF signaling pathway (24 gene counts, p = 1.99 × 10^−11^), and apoptosis pathway (26 gene counts, p = 3.90 × 10^−11^) among the 245 annotated KEGG pathways ([Figure 4](#fig4){ref-type="fig"}F and [Table S5](#mmc1){ref-type="supplementary-material"}), whereas genes in SET II are primarily enriched in metabolic pathways (96 gene counts, p = 2.87 × 10^−17^) among 235 KEGG pathways ([Figure 4](#fig4){ref-type="fig"}G and [Table S6](#mmc1){ref-type="supplementary-material"}). The differentially expressed genes from the four most enriched pathways were further shown as log~2~FPKM value of CDDP-Bi(TPP) combination versus CDDP-alone group ([Figure S3](#mmc1){ref-type="supplementary-material"}E). We found that genes encoding TNF-alpha and several key cysteine-containing pro-apoptotic proteins (Bax, caspase 7, caspase 8) involved in caspase cascade in TNF-induced apoptosis pathway were significantly downregulated. Genes encoding proteins belonging to cytochrome P450 superfamily (*CYP2C44*, *CYP2A5*, *CYP51*, *CYP4F14*), which serves as drug metabolism mediators, were upregulated as shown in [Figure S3](#mmc1){ref-type="supplementary-material"}E and [Table S2](#mmc1){ref-type="supplementary-material"}. This was in accordance with CYP-mediated drug clearance *in vivo* as reported previously ([@bib3], [@bib52]).

Modulation of CDDP-Induced Oxidative Stress, Energetic Metabolism Impairment by Bi(TPP) {#sec2.5}
---------------------------------------------------------------------------------------

The Bi(TPP)-induced alteration in mRNA expression levels was confirmed in HK-2 cells by reverse-transcriptase PCR (RT-PCR). According to the RT-PCR data shown in [Figure 5](#fig5){ref-type="fig"}A, the expression levels of *MT1A*, *MT2A*, and *SLC22A1* were slightly increased by 2.30-, 2.62-, and 1.65-folds, respectively, whereas that of cytochrome P450 superfamily (*CYP2C44*, *CYP2A5*, *CYP5*1, *CYP4F14*) were generally upregulated by more than 3-fold. In contrast, the expression level of *SLC47A1* was increased by 19.6-fold, which may refer to enhanced effluxing capacity toward CDDP ([@bib48]). Interestingly, we observed that the gene expression levels of glutathione-S-transferases (GSTs) were dramatically increased at cellular level, in particular that of *GSTA1*, *GSTA3*, and *GSTM5* being increased by 39.9-, 454.9- and 28.5-fold, respectively. GSTs are a family of multifunctional enzymes that could modulate CDDP-induced generation of ROS by catalyzing the conjugation of GSH with electrophilic substrates ([@bib15], [@bib26]). Any ROS accumulation beyond the cellular antioxidant capacity depolarizes mitochondrial membrane potential (ΔΨm, MMP), a marker for mitochondrial activity, and subsequently leads to a compromised adenosine triphosphate (ATP) production *in cellulo* ([@bib21], [@bib37]).Figure 5Bi(TPP) Modulates CDDP-Induced Oxidative Stress, Energetic Metabolism Impairment(A) The relative fold changes of the expression levels for selected genes in HK-2 cells after Bi(TPP) (10 μM) treatment in comparison to non-treated group, which was determined by RT-PCR.(B) GST activity determination in HK-2 cells after treatment with Bi(TPP) at gradient concentrations.(C) Cellular ROS levels in HK-2 cells after treatment with CDDP (20 μM) or CDDP in combination with a range of Bi(TPP) concentrations.(D) ATP levels in HK-2 cells after treatment with CDDP (40 μM) or CDDP in combination with gradient concentrations of Bi(TPP).(E) Platinum content in HK-2 cells exposed to a range of Bi(TPP) concentrations. (B--E) Mean value of three replicates are shown, and error bars represent means ± SEM in experiment above. ∗p \< 0.05, ∗∗p \< 0.01, and ∗∗∗p \< 0.001, Student\'s t test, with the significance in comparison to the group of Bi(TPP) concentration at 0 μM for (B, D, and E) and to control group for (C).

GST activity was measured in HK-2 cells by spectrometrically monitoring GST-catalyzed reaction between GSH and the GST substrate, CDNB (1-chloro-2,4-dinitrobenzene), to produce a GS-DNB conjugate. The treatment of Bi(TPP) led to the increase of activity from 46.8 to 95.4 μmol min^−1^ per 10^6^ cells in a dose-dependent manner ([Figure 5](#fig5){ref-type="fig"}B). This corresponded with the RT-PCR data that Bi(TPP) induced the production of GST. The cellular ROS level was increased to 174.5% after exposure of HK-2 cells to CDDP for 24 h. However, such an increase was almost completely prevented by Bi(TPP) at 10 μM or higher concentrations ([Figure 5](#fig5){ref-type="fig"}C). We next examined the cellular MMP and ATP levels. Bi(TPP) ameliorated the loss of mitochondrial membrane potential (ΔΨm, MMP) caused by CDDP and scarcely altered ΔΨm when used alone ([Figure S4](#mmc1){ref-type="supplementary-material"}). Bi(TPP) increased the ATP level from 148.5 to 222.1 nM/10^4^ cells in a dose-dependent manner ([Figure 5](#fig5){ref-type="fig"}D). Notably, in a separate experiment, we observed greatly reduced cellular platinum level by nearly 4-fold upon pretreatment of cells with Bi(TPP) at 100 μM ([Figure 5](#fig5){ref-type="fig"}E). This was in accordance with the diminished renal platinum level found in mice ([Figure 2](#fig2){ref-type="fig"}C), which may be due to the formed GS-platinum complex, bis-(glutathionato)-platinum(II) being effluxed from renal cells in an ATP-dependent manner([@bib30], [@bib56]).

Amelioration of CDDP-Induced Caspase-Dependent Apoptosis by Bi(TPP) {#sec2.6}
-------------------------------------------------------------------

Based on bioinformatics analysis, we further explore the Bi(TPP)-mediated detoxification in caspase-dependent apoptosis pathway. It has been demonstrated that CDDP-induced nephrotoxicity occurred primarily through programmed cell death (apoptosis) ([@bib12], [@bib22]). We then examined the apoptosis of CDDP treated HK-2 cells with or without pretreatment of Bi(TPP) and Zn(TPP) by flow cytometry. We found that CDDP-Bi(TPP) treatment markedly induced cell proliferation by 79.6%, whereas pretreatment of Zn(TPP) led to cell proliferation by 57.4%, similar to that of CDDP treatment alone (53.2%). In accordance, significant reduction in the percentage of cells undergoing apoptosis to 10.5% was observed in Bi(TPP)-CDDP treatment; in comparison, 23.6% and 36.8% of cell apoptosis were noted in Zn(TPP)-CDDP and CDDP-only groups, respectively ([Figure 6](#fig6){ref-type="fig"}A), indicating the pretreatment of Bi(TPP) prevents cells from apoptosis.Figure 6Bi(TPP) Ameliorates CDDP-induced Caspase-dependent Apoptosis(A) Apoptosis analysis of HK-2 cells upon treatment with vehicle, CDDP, Bi(TPP), Bi(TPP)+CDDP, Zn(TPP), and Zn(TPP)+CDDP by flow cytometry.(B) Representative immunoblots of HK-2 cells treated with vehicle (DMSO), Bi(TPP) (40 μM), CDDP (20 μM), or their combination for 24 h. Blots were probed with antibodies for Bax (21 kDa), Bcl-2 (26 kDa), caspase 3 (active fragment, 19 kDa), caspase 7 (active fragment, 20 kDa), caspase 8 (active fragment, 43 kDa), caspase 9 (active fragment, 37 kDa), TNF-alpha (16 kDa), p53 (53 kDa), cytochrome *c* (14 kDa), and β-actin (42 kDa).(C) Dose-dependent manner of blots from HK-2 cells treated with escalating concentrations of Bi(TPP). Antibody of metallothionein1+ metallothionein2 (14 kDa) was used.(D and E) Cellular thermal shift assays showing the binding of Bi(III) to (D) caspase 3 and (E) caspase 9 in HK-2 cell with ΔTm = 3.10°C and 2.17°C, respectively. Data are represented as mean ± SEM.(F) Inhibition profiles of caspase 3 and caspase 9 by Bi(TPP) with IC~50~ values of 2.19 μM and 0.53 μM, respectively. Data are represented as mean ± SEM.

Western blot analysis of HK-2 cells treated with CDDP revealed that TNF, apoptotic regulator Bax, and active caspases, i.e., caspase 3, caspase 7, caspase 8, and caspase 9, that mediate cell death in CDDP-induced nephrotoxicity, were upregulated. However, such upregulations were prevented upon supplementation of Bi(TPP) to the cell prior to CDDP treatment, whereas an increase in the expression levels of anti-apoptotic protein Bcl-2 was observed ([Figure 6](#fig6){ref-type="fig"}B). Notably, Bi(TPP) did not affect the expression of p53, indicating that the amelioration of CDDP-induced apoptosis by Bi(TPP) was p53 independent. Moreover, we observed dose-dependent effects on the expression levels of caspase 3, caspase 7, caspase 8, caspase 9, Bax, and Bcl-2 upon treatment of cells by varying concentrations of Bi(TPP) in the absence of CDDP ([Figure 6](#fig6){ref-type="fig"}C), revealing that Bi(TPP) itself suppressed the apoptotic signaling in cells to a certain extent. Bi(III) has been shown to be able to inhibit enzyme activity in cells *via* binding to key cysteines in the active sites of enzymes ([@bib13], [@bib69]). We then examined whether Bi(TPP) could target caspases 3/7 in cells. By using cellular thermal shift assay ([@bib31]), we show that melting temperatures of both caspase 3 and caspase 7 were decreased by Bi(TPP) ([Figures 6](#fig6){ref-type="fig"}D and 6E), indicative of binding of Bi(III) to the enzymes. Moreover, we observed the reduced caspase activity in lysate extracted from HK-2 cells treated with Bi(TPP) in the absence of CDDP ([Figure S5](#mmc1){ref-type="supplementary-material"}). We further carried out an enzymatic assay on recombinant proteins and observed that the activity of cleaved caspase 3 and caspase 9 were inhibited by Bi(TPP) with IC~50~ of 2.19 μM and 0.53 μM, respectively ([Figure 6](#fig6){ref-type="fig"}F). Our combined data provided evidence that Bi(TPP) protects CDDP-induced cell death by maintaining cellular redox, preserving mitochondrial function, facilitating the excretion of renal platinum, and attenuating caspase-dependent apoptosis.

CDDP Antineoplastic Performance in Neuroblastoma Mouse Pretreated with Bi(III) Compounds {#sec2.7}
----------------------------------------------------------------------------------------

It is of vital importance to examine whether the pre-administration of tested Bi(III) compounds would ameliorate CDDP-induced nephrotoxicity, without interfering with the anti-tumor response of CDDP. We evaluated the antineoplastic activity of CDDP with or without pretreatment of Bi(III) compounds in an orthotopic neuroblastoma xenograft model. The neuroblastoma cells SKNLP were stably transfected with the luciferase gene and orthotopically inoculated at the adrenal area of SCID Beige mice as previously described ([@bib8]). Mice were pre-treated with Bi(III) compounds prior to CDDP treatment as schemed in [Figure 7](#fig7){ref-type="fig"}A, and the tumor burden was monitored by bioluminescence imaging. We found that the tumor size was significantly decreased with averaged diameter from 19.3 mm in non-treated group to 6.7 mm in CDDP-alone treatment group for three weeks ([Figure 7](#fig7){ref-type="fig"}B).Figure 7Bi(III) Compounds Does Not Attenuate the Anticancer Properties of CDDP on Adrenal Tumors(A) Schematic representation of the experimental design.(B) Photos showing the size of tumor dissected three weeks after CDDP treatment. Four mice were used in vehicle, CDDP + vehicle, CDDP + Bi(NAC)~3~, and CDDP + Bi(TPP) group; one mouse in CDDP-alone group died owing to the toxicity of CDDP during the experimental period; five mice were used in CDDP + BiZn.(C) Luminescence images of the SKNLP neuroblastoma cells growth in the identical mice as shown in (B). The scale of luminescent flux is shown in the bar chart right to the luminescence image.(D) Luminescent scans of dissected liver and lung from the same mice in (B), showing the metastasis of SKNLP cells from adrenal gland to either liver or lung. The scale of luminescent flux is shown in the bar chart right to the luminescence image.

Pre-administration of either Bi(TPP) or Bi(NAC)~3~ or BiZn led to almost no changes in tumor size, suggesting that pretreatment of Bi(III) compounds have negligible effects on the anti-tumor action of CDDP ([Figure 7](#fig7){ref-type="fig"}B). On the contrary, the bioluminescence imaging showed no significant difference in total flux in mice receiving treatment of CDDP alone or CDDP-Bi(III) combination three weeks after treatment completion, which was far lower than that in non-treated group ([Figure 7](#fig7){ref-type="fig"}C). Furthermore, no significant tumor metastasis to liver or lung was observed in either CDDP-alone or combination groups, in contrast to non-treated group ([Figure 7](#fig7){ref-type="fig"}D). We demonstrated that the tested Bi(III) compounds, i.e., Bi(TPP) and Bi(NAC)~3~, do not compromise CDDP antineoplastic activity against neuroblastoma, and concurrently nephroprotection role of Bi(TPP) is not due to its capability of sequestration of CDDP in the blood.

Discussion {#sec3}
==========

The use of highly successful anticancer drug CDDP is limited by its severe side effects, in particular nephrotoxicity ([@bib53]). This nephrotoxicity is mainly attributable to preferential accumulation of CDDP in renal proximal tubules, primarily in the epithelial tubular cells of the S3 segment, which subsequently favors the renal platinum uptake systems ([@bib17]). A number of nephroprotective agents have been tested or even put on clinical trial, such as cimetidine (and Imatinib as OCT-2 substrate), amifostine (Ethyol as antioxidants), trichostatin A (and suberoylanilide hydroxamic acid as p53 inhibitor), quercetin (as TNF-α inhibitor), and so on ([@bib14], [@bib33], [@bib64]). However, the protective effects of most agents are partial and few of them were not to interfere with antitumor efficacy of CDDP in the experimental context ([@bib36]). Moreover, some cytoprotectors exert severe adverse effects ([@bib54]). Currently there is no satisfactory strategy to reduce CDDP-induced nephrotoxicity without compromising the anticancer activity of CDDP.

In this study, we identify two protective Bi(III) compounds, Bi(TPP) and Bi(NAC)~3~, based on a cell-based screening, nevertheless the *in vitro* activity of the latter was not efficiently translated in animal models. Co-administration of Bi(TPP) diminished the renal damage and increased the survival rate of mice receiving a lethal dose of CDDP, thus a high dose of CDDP could be administrated to patients. Our results suggest that once Bi(TPP) is absorbed into the bloodstream, it is rapidly metabolized and distributed to the kidney, during which the plasma bismuth content remains well under the documented safety level (50 μg L^−1^)) or alarm level (100 μg L^−1^) ([@bib4]). The pharmacokinetics profiles show that in comparison to BiZn, Bi(TPP) possessed lower clearance rate and higher AUC~0--8h~ value (104.2 μg L^−1^ h of Bi(TPP) versus 78.3 μg L^−1^ h of BiZn) ([Table S1](#mmc1){ref-type="supplementary-material"}), which is in line with its superior protective effectiveness. In this regard, longer duration and less peak-to-trough variations might optimize the dosing frequency and potentially improve oral efficacy.

Porphyrin ligands are well documented to be able to modify the lipophilicity of metal complex, which mediates the membrane permeability of metal complexes and metal uptake *via* passive diffusion in a membrane-potential dependent manner ([@bib23]). This is confirmed by our data that the protective potency of Bi(III) porphyrin complexes is correlated with the ClogP value of porphyrin ligands ([Figure 3](#fig3){ref-type="fig"}C). Protective potency of Bi(TPP) may be rooted from the metal coordination environments and synergized function with porphyrin ligands. Nevertheless, we conclude that an appropriate lipophilicity is one of the important factors that contributes to the protective potency of Bi(TPP). The precise mode of action(s) among different Bi(III) porphyrin compounds still needs further investigation.

We then perform a comprehensive mechanistic study of the protective role of Bi(TPP) by transcriptome analysis and bioassays. We show that Bi(TPP) confers protection against CDDP-induced nephrotoxicity not primarily owing to the induction of MT ([Figures 5](#fig5){ref-type="fig"}A and [6](#fig6){ref-type="fig"}C) but rather to other multiple protective mechanisms. We first observe that the Bi(TPP) induced upregulation of GSTs ([Figures 5](#fig5){ref-type="fig"}A and 5B), members of superfamily of phase II detoxifying enzymes that protect cells by catalyzing the conjugation reactions of toxic compounds, e.g. CDDP with GSH, to form corresponding GS-Pt conjugate ([@bib1]). We also note the elevated transcript level of platinum efflux transporters, e.g. MATE1/SLC47A1, which may account for the diminished renal platinum in kidney from Bi(TPP)-CDDP co-administration group, yet the level of platinum influx transporters, e.g. OCT2/SLC22A2, was not significantly changed ([Figure 5](#fig5){ref-type="fig"}A). Therefore, GSTs and efflux transporters, e.g. MATE1/SLC47A1, may synergise to increase the discharge of GS-Pt conjugate from renal cell as suggested by both our data ([Figures 2](#fig2){ref-type="fig"}C and [5](#fig5){ref-type="fig"}E) and previous reports ([@bib65]). In parallel, we demonstrate that Bi(TPP) lowers the CDDP-induced ROS in dose-dependent manner, which may be owing to the overexpression of alpha class GSTs, i.e., GSTA1, GSTA2, and GSTA3, that could provide antioxidant effect toward various ROS ([@bib11], [@bib62]).

Apoptosis is a mode of programmed cell death that is used by multicellular organisms to dispose of irreparably damaged cells and is executed by a family of caspases ([@bib19]). CDDP-induced apoptosis occurs *via* activation of caspases, e.g. caspase 3, 8, and 9, in the apoptotic pathway ([@bib12], [@bib27]). Our combined data reveal Bi(TPP) mediates the caspase cascade by either preventing the CDDP-induced caspases upregulation or directly inhibiting the caspase activity ([Figures 6](#fig6){ref-type="fig"}B, 6C, 6F, and [S3](#mmc1){ref-type="supplementary-material"}E). The former may result from the hindered activation of apoptosis signaling pathways by less ROS ([@bib55]), which is mediated by Bi(TPP); the latter may be due to the binding of Bi(III) to cysteine residues at the caspase active site, because Bi(III) has been proven to inhibit enzyme activity through binding to the key cysteine in the active site ([@bib69]).

Renal proximal tubules are largely dependent on ATP generation by mitochondrial oxidative phosphorylation and thus particularly susceptible to mitochondrial damage ([@bib67], [@bib70]). We find that Bi(TPP) promotes the generation of ATP, possibly due to Bi(TPP)-induced upregulation of cytochrome *c* ([Figures 6](#fig6){ref-type="fig"}B and 6C) and cytochrome *c* oxidase (encoded by COX8, complex IV) ([Figure 5](#fig5){ref-type="fig"}A and [Table S2](#mmc1){ref-type="supplementary-material"}), both of which serve as indispensable parts of the mitochondrial electron transport chain (ETC). Cytochrome *c* is a multi-functional enzyme involved in life-sustaining functions, i.e., respiration and ROS scavenging, and in programmed cell death, i.e., apoptosis ([@bib29]). The increased cytochrome *c* may also account for the decreased of ROS level, because it was perceived as an "ideal antioxidant" ([@bib50]). Although, the dramatic increase of cytochrome *c* may slightly lead to cell apoptosis ([Figure 6](#fig6){ref-type="fig"}A), it may still contribute to scavenging generated ROS and preventing ATP depletion caused by CDDP ([Figures 5](#fig5){ref-type="fig"}C and 5D). We note that Bi(III) could bind to apo-form of cytochrome *c* ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B); however, such binding did not trigger the activation of caspase cascade based on cell-free caspase activation assay ([Figure S6](#mmc1){ref-type="supplementary-material"}C). It could be inferred that the binding of Bi(III) triggers certain feedback regulation to produce more cytochrome *c*. However, it is not clear why the significant upregulation of cytochrome *c* dose not initiate severe apoptotic cell death. This may be correlated with coherent upregulation of cytochrome *c* oxidase mediated by Bi(TPP) ([@bib59]), but the mechanistic insights of why cytochrome *c* is upregulated by Bi(TPP) and how it is regulated to be more "protective" here than apoptotic warrant further studies in the future.

A highly significant and clinically relevant finding of this study is that Bi(TPP) provides nephroprotection without compromising the antitumor effect of CDDP in an *in vivo* neuroblastoma orthotopic model. Bi(TPP) does not affect the therapeutic effectiveness of CDDP in either primary adrenal site or metastatic sites, e.g. lung and liver. Since some porphyrins e.g. 5, 10, 15, 20-tetra-(N-methyl-4-pyridyl)porphyrin \[TMPyP4(P4)\] and related manganese porphyrin ([@bib24], [@bib44], [@bib51]) were reported to have anticancer activities when bound to G-quadruplex, it could be deduced that a nephroprotective metallo-porphyrin could exert certain degree of anticancer activity under rational design. N-acetylcysteine (NAC) has also been shown to display antitumor activity either used alone or combined with other anticancer drugs such as CDDP and doxorubicin ([@bib16], [@bib42], [@bib45]). It is likely that Bi(NAC)~3~ or its analogues could be further developed as a bifunctional partner of anticancer drugs upon optimization of pharmacokinetics and pharmacodynamics, so that they could simultaneously protect normal cells and synergize with an anticancer drug in its antineoplastic performance.

In summary, we demonstrate that Bi(TPP) could serve as a new type of potent protective agent against CDDP-induced nephrotoxicity without compromising its anticancer properties. Distinct from previously reported bismuth drugs that exert protective role through MT-dependent pathway, Bi(TPP) inactivates caspase-dependent apoptotic pathway, maintains energy supply, and eliminates the renal platinum. Our studies suggest that Bi(TPP) may be incorporated into CDDP-based chemotherapy regimens to ameliorate CDDP-induced nephrotoxicity in patients receiving low-dosed CDDP or those with refractory tumors receiving high-dosed CDDP. Our findings provide the potentials to revive the clinical usage of highly effective anticancer drug CDDP.

Limitations of the Study {#sec3.1}
------------------------

Some limitations to the findings of this study must be acknowledged. First, we observed the demetallation of Bi(TPP) upon long period exposure to light and moisture. The enhancement of both stability and solubility of the complex in aquous medium either through structural or through compositional optimization would probably improve its *in vivo* protective potency. In addition, further optimization of pharmacokinetics profiles of the drug candidate may be required to achieve lower clearance and longer half-life while maintaining its promising potency and low toxicity. One additional limitation of the study is the difficulty in assessing precise protective mechanisms in primary human renal epithelial cells. Although we demonstrate that Bi(TPP) exerts an MT-independent protective action in HK-2 cell, more *in vitro* and *in vivo* assays are necessary to rule out cell-line-specific phenomenon. Further study is also required to unveil whether Bi(TPP) and/or other Bi(III) porphyrins as well as other protective metallo-porphyrins share the same or similar protective mode of action(s).

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec1}
==========================

Data and code related to this paper may be requested from the authors. All the mRNA sequencing data could be found in [Data S1](#mmc2){ref-type="supplementary-material"}.

Supplemental Information {#appsec3}
========================

Document S1. Transparent Methods, Figures S1--S6, and Tables S1, S2, S4--S8Data S1. Raw mRNA-seq Data for Analysis, Related to Figure 4This file include all the IDs, names, locus, and FPKM values for the genes in three biological replicates from groups of vehicle, BiZn, Bi(TPP), CDDP, BiZn + CDDP, and Bi(TPP)+CDDP, respectively.Table S3. GO Term of Biological Process Annotation for SET I, Related to Figure 4This file lists all the GO enrichement terms to present the annotations in biological process for SET 1 genes

This work was supported by 10.13039/501100010428Innovation and Technology Fund, Hong Kong (ITS/124/17), Research Grants Council of Hong Kong SAR (R7070-18) and Norman & Cecilia Yip Foundation (University of Hong Kong). We thank Kenneth Raymond (UC Berkeley) and Roman Vilar (Imperial College London) for helpful comments.

Author Contributions {#sec5}
====================

H.S., H.L., C-F.C., and Z.Z. conceived idea and designed experiments; R.W. synthesized the compounds; R.W. and S.Y. performed all the enzyme-based and cell-based experiments. R.M. and S.Y. conducted *in vivo* nephrotoxicity experiments. R.W. and Y.W. performed the transcriptomic analysis. C.C. performed the *in vivo* tumor model experiments. Y.Z. performed the pharmacokinetics study. R.W., H.L., and H.S. principally wrote the manuscript with input from all coauthors.

Declaration of Interests {#sec6}
========================

H.S., C-F. C., R.W., C.C., and H.L. have filed a patent application (US Provisional Application No. 62/193,282) related to the Bi(III) compounds reported in this manuscript.

Supplemental Information can be found online at <https://doi.org/10.1016/j.isci.2020.101054>.

[^1]: Lead Contact
